Crossing the next frontier
to give you a fair chance to fight
At Exeliom Biosciences, we develop novel therapeutic approaches to unleash
the therapeutic potential of key players in the Microbiome - Host interactions to fight
immune-mediated diseases, starting with inflammatory bowel diseases
about us
crossing
the next frontier...
There is a time to think. There is a time to act. There is a time to contemplate.
There is a time to explore. There is a time to analyze. There is a time to conquer.
Conquer the human microbiome. Conquer the pain you feel every day.
For we are ready, fueled by the hope of patients, physicians, and scientists.
Ready to succeed where no one else yet has dared to go. Ready to cross the next frontier.
... to give you
a fair chance to fight
You, the patients, are the reason why leading researchers have joined forces in a pioneering
translational approach called “Human Discovery First”. Giving you a fair chance to fight is why
we discovered unexplored therapeutic solutions based on your gut microbiome,
and why we founded Exeliom Biosciences.
EXL01
Our research has led us to discover that patients suffering from inflammatory bowel diseases
lack a crucial bacterium and, therefore, do not have a fair chance to fight their conditions.
We have developed a single bacterial strain drug candidate to deliver first-in-class
microbiome-based therapeutics for the treatment of inflammatory bowel diseases (IBD),
starting with Crohn’s Disease as a first indication.
partnerships
At Exeliom Biosciences, we are always thinking of the future without leaving the present behind.
And this future, we intend to build it through partnerships.
Discover
